Skip to main content
. 2020 Feb 17;25(4):888. doi: 10.3390/molecules25040888

Table 4.

Cytotoxic activities (GI50, TGI and LC50) of compounds 11, 13, 14, and 15 against 60 human cancer cell lines in vitro. Values where GI50 < 100 nM or TGI/LC50 < 10 μM are highlighted in bold.

11 13 14 15
Leukemia GI50 (μM) TGI (μM) LC50 (μM) GI50 (μM) TGI (μM) LC50 (μM) GI50 (μM) TGI (μM) LC50 (μM) GI50 (μM) TGI (μM) LC50 (μM)
CCRF-CEM 19.6 64.1 >100 2.25 >100 >100 3.57 >100 >100 0.4 >100 >100
HL-60 (TB) >100 >100 >100 2.16 >100 >100 2.79 34.9 >100 0.32 >100 >100
K-562 5.03 >100 >100 0.47 >100 >100 0.59 >100 >100 0.28 >100 >100
MOLT-4 5.46 >100 >100 2.66 >100 >100 4.08 >100 >100 0.56 >100 >100
RPMI-8226 7.03 >100 >100 2.87 >100 >100 4.51 >100 >100 0.39 >100 >100
SR 4.44 >100 >100 0.40 >100 >100 0.53 >100 >100 0.25 >100 >100
Non-Small-Cell Lung Cancer
A549/ATCC 1.71 3.75 8.23 2.11 >100 >100 5.16 >100 >100 0.72 94.7 >100
EKVX 9.37 62.4 >100 3.35 >100 >100 4.83 5.6 >100 0.64 >100 >100
HOP-62 2.62 8.19 35.7 3.23 >100 >100 3.55 >100 >100 0.56 21.7 >100
HOP-92 2.13 6.71 90.1 3.51 >100 >100 3.76 23.7 >100 1.95 21.3 >100
NCI-H226 2.28 6.48 >100 4.11 >100 >100 4.38 28.8 >100 1.25 71.2 >100
NCI-H23 3.07 11.6 49.6 4.75 >100 >100 4.22 52.6 >100 0.93 28 >100
NCI-H233M >100 >100 >100 n.d. >100 >100 5.98 27.4 >100 0.52 49.2 >100
NCI-H460 2.59 6.68 >100 2.89 >100 >100 3.37 12 >100 0.36 12.5 93.6
NCI-H552 6.77 >100 >100 1.79 >100 >100 2.67 27.1 >100 0.24 21.5 >100
Colon Cancer
COLO 205 8.04 >100 >100 n.d. >100 >100 9.92 >100 >100 5.13 >100 >100
HCC-2998 >100 >100 >100 n.d. >100 >100 6.07 >100 >100 1.94 29.1 >100
HCT-116 1.83 4.06 8.99 3.36 >100 >100 3.31 >100 >100 0.42 >100 >100
HCT-15 3.28 21.1 >100 0.68 >100 >100 1.65 >100 >100 0.06 >100 >100
HT29 6.48 >100 >100 3.25 >100 >100 3.64 >100 >100 3.18 13.6 >100
KM12 8.17 >100 >100 2.38 >100 >100 2.76 55.2 >100 0.2 15.3 >100
SW-620 3.56 >100 >100 0.73 >100 >100 2.5 >100 >100 0.35 >100 >100
CNS Cancer
SF-268 4.94 26.1 >100 4.49 >100 >100 4.71 48.2 >100 0.6 31 >100
SF-295 2.94 9.13 32.6 2.36 >100 >100 2.98 13.2 43.2 0.3 3.79 99.3
SF-539 2.21 5.50 20.5 3.10 >100 >100 2.73 10.4 36.3 0.28 1.25 18.2
SNB-19 4.17 21.7 >100 2.98 >100 >100 2.99 15.7 >100 0.48 20.5 >100
SNB-75 1.65 4.41 14.9 n.d. n.d. n.d. 2.39 8.5 59.6 0.17 0.64 44.2
U251 2.01 4.45 9.84 3.04 >100 >100 3.63 >100 >100 0.41 16 >100
Melanoma
LOX IMVI 4.74 22.6 >100 2.75 >100 >100 3.41 >100 >100 0.51 >100 >100
MALME-3M 3.17 >100 >100 2.43 >100 >100 2.13 11.9 57.6 0.63 >100 >100
M14 27.6 >100 >100 2.38 >100 >100 n.d. n.d. n.d. 0.5 >100 >100
MDA-MB-435 6.03 >100 >100 0.31 >100 >100 0.36 2.03 >100 0.1 0.33 >100
SK-MEL-2 15.1 38.0 95.7 2.44 >100 >100 5.62 34.2 >100 0.79 78.5 >100
SK-MEL-28 n.d. >100 >100 n.d. >100 >100 3.64 25.8 >100 2.78 >100 >100
SK-MEL-5 4.10 25.4 >100 2.39 >100 >100 3 9.58 42.4 0.17 3.25 >100
UACC-257 >100 >100 >100 n.d. >100 >100 6.72 63.5 >100 >100 >100 >100
UACC-62 6.58 >100 >100 2.89 >100 >100 2.39 12.8 61.1 0.3 14 >100
Ovarian Cancer
IGROV1 3.61 15.9 86.3 3.20 >100 >100 2.98 18.5 94.5 0.23 25.5 >100
OVCAR-3 2.12 4.12 7.99 1.72 4.91 >100 2.05 5.2 21.5 0.22 1.59 >100
OVCAR-4 2.45 5.94 >100 3.38 >100 >100 4.49 47.8 >100 8.9 41.5 >100
OVCAR-5 7.18 >100 >100 >100 >100 >100 4.82 27.3 >100 0.55 22.6 >100
OVCAR-8 3.67 3.21 >100 3.61 >100 >100 4.65 >100 >100 0.54 17.1 >100
NCI/ADR-RES 3.45 22.5 >100 1.28 >100 >100 1.99 18 >100 0.45 26.7 >100
SK-OV-3 14.9 50.7 >100 5.56 >100 >100 3.57 17.9 96.4 0.4 14.1 74.3
Renal Cancer
786-0 2.01 4.15 8.56 4.42 >100 >100 5.15 27 >100 1.04 20.7 91.4
A498 4.05 17.8 65.2 2.48 n.d. >100 3.08 13.9 65.8 0.34 14 75.9
ACHN 2.91 9.63 60.5 4.25 >100 >100 3.38 13 41.5 0.59 >100 >100
CAKI-1 3.74 18.7 78.2 2.77 >100 >100 4.24 20.3 73.5 0.28 15 80.3
RXF 393 2.21 6.34 30.1 2.45 9.56 >100 1.74 5.34 28.1 0.21 0.79 38.1
SN12C 4.02 >100 >100 4.05 >100 >100 3.5 17.6 94.5 0.79 60.4 >100
TK-10 1.88 3.71 7.30 n.d. >100 >100 10.4 28.6 78.5 10.7 79.4 >100
UO-31 2.44 n.d. >100 n.d. >100 >100 3.57 21.5 >100 0.62 22.9 98.3
Prostate Cancer
PC-3 5.75 >100 >100 3.30 >100 >100 5.13 41.6 >100 0.52 27.2 >100
DU-145 7.97 >100 >100 3.78 >100 >100 4.35 16.4 51.7 0.4 2.14 >100
Breast Cancer
MCF7 7.40 >100 >100 0.82 >100 >100 1.63 >100 >100 0.03 >100 >100
MDA-MB-231/ATCC 2.04 5.26 22.6 3.58 >100 >100 3.96 18.4 68.2 1.05 22.4 >100
HS 578T 2.60 7.80 >100 2.46 >100 >100 3.61 32.6 >100 0.3 2.45 >100
BT-549 5.19 38.9 >100 4.03 >100 >100 4.96 37.2 >100 0.77 >100 >100
T-47D 2.54 n.d. >100 2.96 >100 >100 4.36 >100 >100 0.21 >100 >100
MDA-MB-468 4.95 35.8 >100 0.38 3.03 >100 1.5 6.42 >100 0.13 0.64 >100